Frequency of the CHEK2 1100delC mutation among women with early-onset and bilateral breast cancer

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Ding, Dapeng ^a   Zhang, Ying ^b   He, Xiaofeng ^c   Meng, Wei ^a   Ma, Wenli ^a   Zheng, Wenling ^d  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c CHANGZHI MEDICAL COLLEGE   (China)

^d Genome Centre of Southern China   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN SERINE THREONINE KINASE;

BREAST CANCER; CANCER RISK; FAMILIAL CANCER; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; IRELAND; LETTER; ONSET AGE; POPULATION RESEARCH; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; NOTE;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84862787391     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3159     Document Type: Letter

References (8)

1. Desrichard A, Bidet Y, Uhrhammer N, Bignon YJ. CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res 2011, 13:R119. 10.1186/bcr3062, 3326561, 22114986.
2. Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A, Pietschmann A, Nestle-Krämling C, Rhiem K, Hüttner C, von Lindern C, Dall P, Kiechle M, Untch M, Jonat W, Meindl A, Scherneck S, Niederacher D, Schmutzler RK, Arnold N. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 2004, 110:320-325. 10.1002/ijc.20073, 15095295.
3. Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, Pierl CB, Brüning T, Ko Y, Benner A, Wichmann HE, Brauch H, Hamann U; GENICA N. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer 2005, 41:2896-2903. 10.1016/j.ejca.2005.04.049, 16239104.
4. de Jong MM, Nolte IM, Te Meerman GJ, van der Graaf WT, Oosterom E, Bruinenberg M, Steege G, Oosterwijk JC, van der Hout AH, Boezen HM, Schaapveld M, Kleibeuker JH, de Vries EG. No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors. Eur J Cancer 2005, 41:1819-1823. 10.1016/j.ejca.2005.04.035, 16043347.
5. McInerney NM, Miller N, Rowan A, Colleran G, Barclay E, Curran C, Kerin MJ, Tomlinson IP, Sawyer E. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat 2010, 121:203-210. 10.1007/s10549-009-0540-9, 19763819.
6. Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007, 121:2661-2667. 10.1002/ijc.23026, 3090684, 17721994.
7. Chekmariova EV, Sokolenko AP, Buslov KG, Iyevleva AG, Ulibina YM, Rozanov ME, Mitiushkina NV, Togo AV, Matsko DE, Voskresenskiy DA, Chagunava OL, Devilee P, Cornelisse C, Semiglazov VF, Imyanitov EN. CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res Treat 2006, 100:99-102. 10.1007/s10549-006-9227-7, 16758118.
8. Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, van de Wetering T, Narod SA, Lubiŕski J. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 2007, 102:119-122. 10.1007/s10549-006-9320-y, 16897426.